More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.66B
EPS
-3.26
P/E ratio
--
Price to sales
8.61
Dividend yield
--
Beta
0.430193
Previous close
$29.06
Today's open
$29.90
Day's range
$27.97 - $29.99
52 week range
$27.25 - $86.74
show more
CEO
Brett P. Monia
Employees
1480
Headquarters
Carlsbad, CA
Exchange
Nasdaq Global Select
Shares outstanding
166545100
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]). TRYNGOLZA is the first and only RNA-targeted therapy authorized in the EU for adults with sHTG ≥880 mg/dL (≥10 mmol/L). The app.
Business Wire • 19 hours ago

Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer's disease
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer's disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference showed slowing of clinical decline across measures.
Business Wire • 6 hours ago

Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start
Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CEO Brett Monia said at the UBS Global Biopharma Conference.
MarketBeat • Nov 16, 2026

Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky
TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on behalf of shareholders who lost money.
PRNewsWire • Nov 16, 2026

Ionis Pharmaceuticals, Inc. (IONS) Presents at UBS Global Biopharma Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. ( IONS ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Joon Lee - UBS Investment Bank, Research Division Presentation Joon Lee UBS Investment Bank, Research Division All right. We'll get started.
Seeking Alpha • Nov 16, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals, Inc. (IONS)
Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation gets underway Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation gets underway
GlobeNewsWire • Nov 12, 2026

Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).
GlobeNewsWire • Nov 12, 2026

Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to be presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona. Multiple presentations will demonstrate the long-term efficacy and safety of DAWNZERA in the OASISplus open-label extension (OLE) and switch cohort.
Business Wire • Nov 12, 2026

Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings
IONS plunges as slower Tryngolza sales, reduced guidance and disappointing Wainua royalties rattle investors.
Zacks Investment Research • Nov 11, 2026

AMG TimesSquare Mid Cap Growth Fund Q3 2026 Portfolio Update
During this quarter, AMG TimesSquare Mid Cap Growth Fund performed in line with the Russell Midcap® Growth Index. Our leading contributors were software and health care technology companies that exceeded expectations for the fiscal quarter, with each pointing to AI as an expanding source of demand. Our overweight in Industrials, one of the benchmark's weakest sectors, also weighed on allocation.
Seeking Alpha • Nov 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Ionis Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.